Sensible Biotechnologies
Cell-based mRNA manufacturing
About Sensible Biotechnologies
Sensible Biotechnologies is a Slovakia-based company founded in 2021, now around 31 people. It has raised $45M in disclosed funding. FundFinder classes it as Health & Bio.
Founded by Marian Kupculak (Chief Science Officer and Co-Founder; previously Max Perutz Labs Vienna, Univerzita Komenského V Bratislave; University of Oxford), Miroslav Gasparek (CEO and Co-Founder; repeat founder; previously Caltech, Exponea (acquired by Bloomreach); University of Oxford).
Its investors also appear on FundFinder's most-active lists for Series A · AI (62 funds), Series A · Healthcare & Wellbeing (54 funds), Series A · DeepTech (53 funds).
Company facts from Harmonic and public filings; team backgrounds from public profiles. Refreshed weekly.
Series A · $27M · Oct 2026
- Amino Collective — Health and bio-focused early-stage firm with offices in London and Berlin, founded in 2020, which closed a €30M second fund to back pre-seed and seed founders across digital health, AI-driven drug discovery and synthetic · cheques £200k+
- BACKED VC — BACKED is the human-centric venture capital fund. · cheques £250k – £3M
- Kaya VC — Prague-based early-stage VC firm (founded 2010 as Enern) that invests from pre-seed to Series A in founders from the CEE region with global ambitions. · cheques £780k – £2.3M
- OTB Ventures — Pan-European deeptech VC (Warsaw and Amsterdam, founded 2017) managing €350m+ across late-seed to Series B in spacetech, AI & automation, fintech infrastructure and cybersecurity; portfolio includes ICEYE and Spacety-adj
- Oxford Science Enterprises — Oxford Science Enterprises a university-partnered venture firm, investing in early-stage life science, AI & software, and deep tech. · cheques £5M – £30M